Information Provided By: 
Fly News Breaks for June 10, 2019
EOLS, AGN
Jun 10, 2019 | 12:34 EDT
Wells Fargo analyst David Maris wrote a flash comment that Evolus' (EOLS) receiving a notice from the EC requesting supplementary information from the EMA/CHMP as part of their review of Nuceiva, a potential competitor to Botox, is a positive for Allergan (AGN), as it delays the marketing authorization application, or MAA, decision for Nuceiva in Europe. Maris kept an Outperform rating on Allergan.
News For AGN;EOLS From the Last 2 Days
There are no results for your query AGN;EOLS
